Therapeutic correction of anemia in patients with chronic heart failure of ischemic origin with iron’s drugs in combination with quercetin
DOI:
https://doi.org/10.14739/2310-1210.2017.5.110090Keywords:
chronic heart failure, anemia, hematinics, quercetinAbstract
The aim of the study was to evaluate the effectiveness of anemia's correction in patients with chronic heart failure of ischemic genesis with iron's drugs in comparison with their combination with quercetin based clinical, cardiohemodynamic characteristic, indicators of erythropoiesis and cytokines.
Materials and methods. Tere were examinated 120 patients with chronic heart failure due to iscemic heart disease and anemia. Chronic heart failure FC II diagnosed in 49 pations, III FK – 42 and FC IV – 29. Patients with CHF and anemia were divided in 2 groups. 1 group recieved standart therapy and iron’s drugs, the 2 group was additionally assigned quercetin. Hemoglobin, serum iron, erythropoetin and ferritin levels were evaluated.
Results. After the therapy, the level of erythrocytes, hemoglobin, hematocrit, serum iron in the first group increased by 5.3, 20.3, 12.8, 40.2 %, respectively, in the II group – by 9.2, 25.6, 14.2 and 62.4 % respectively. The level of erythropoietin before the onset of therapy in both groups significantly exceeded the control indices. After treatment it significantly decreased in the I group by 20.4 %, in II – by 28.2 %. A significant increase of the level of tumor necrosis factor-α, interleukin-1β was determined in both groups of patients with chronic heart failure and anemia, In first group level of tumor necrosis factor -α significantly decreased by 14.2 %, interleukin-1β – on 6.5 %, in II group – by 26.6 % and 28.1 % respectively after the treatment. In the first group the end-diastolic diameter was significantly decreased by 7.7 %, the end-diastolic volume by 9.5 %, the end-systolic diameter by 7.9 %, the end systolic volume by 7.5 %, the ejection fraction increased by 14.4 % and indicators of a 6-minute walk test by 19.4 %, quality of life parameters by 24.2 %, in II group the end diastolic diameter decreased by 11.3 %, the end diastolic volume by 10.2 %, the end systolic diam, eter by 9.4 %, the end systolic volume by 13.6 %, the ejection fraction increased by 18.3 %, the distance of 6-minute walk test improved by 34.0 % the quality of life parameters by 32.9 %.
Conclusions. It has been detected, that anemia’s correction in patients with CHF, who received combination of standart treatment with iron’s drugs accompanied by an increase in the level of erythrocytes, hemoglobin, iron, and decreased level in the initially increased levels of erythropoetin, ferritin, tumor necrosis factor-α, interleykin-1β. Favorable changes in erythropoiesis were accompanied by a positive dynamics of the morphofunctional parameters of the myocardium, the distance during the 6-minute walk test and the quality of life indicators. Quercetin, included in the scheme of therapy of patients with chronic heart faiulure and anemic syndrome, potentiated hematopoietic and hemodynamic effects of therapy.
References
Kuryata, О. V., Karavanskaya, I. L., & Karavanskaya, L. К. (2016). Agregacionnye svojstva trombocitov i klinicheskaya kartina khronicheskoj serdechnoj nedostatochnosti, obuslovlennoj ishemicheskoj bolezn´yu serdca, pri sochetanii s zhelezodeficitnoj anemiej v dinamike lecheniya parenteral´noj formoj trekhvalentnogo zheleza [Aggregation of platelet and clinical picture of chronic heart failure due to ischemic heart disease, in combination with iron-deficiency anemia during the treatment by parenteral form of ferric]. Ukrainskyi medychnyi chasopys, 4(114), 77–81. [in Russian].
Swedberg, К., Young, J. B., Anand, I. S., Cheng, S., Desai, A. S., Diaz, R., et al. (2013). Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. N Engl J Med, 368, 1210–1219. doi: 10.1056/NEJMoa1214865.
Jankowska, E. A., Malyszko, J., Ardehali, H., Koc-Zorawska, E., Banasiak, W., von Haehling, S., et al. (2013). Iron status in patients with chronic heart failure. Eur Heart J., 34(11), 827–834. doi: 10.1093/eurheartj/ehs377.
Larina, V. N., & Bart, B. Ia. (2014). Klinicheskie proyavleniya anemicheskogo sindroma i ego znachenie v techenii khronicheskoj serdechnoj nedostatochnosti u bol´nykh pozhilogo vozrasta [Clinical manifestations of anemia syndrome and its significance in the course of chronic heart failure in elderly patients]. Terapevticheskij arkhiv, 86(3), 53–58. [in Russian].
Rudyk, Yu. S., & Bolotskikh, A. V. (2012). Anemicheskij sindrom pri khronicheskoj serdechnoj nedostatochnosti [Anemic syndrome in chronic heart failure]. Ostrye i neotlozhnye sostoyaniya v praktike vracha, 1, 42–47. [in Russian].
Kleijn, L., Westenbrink, B. D., & van der Meer, P. (2013). Erythropoietin and heart failure: the end of a promise? European Journal of Heart Failure, 15, 479–481. doi: 10.1093/eurjhf/hft058.
Kravchun, P. G., Ryndina, N. G., Babadjan, V. D., Pashtiani, R. V., & Litvinenko, E. Yu. (2014). Kompleksnaya ocenka stepeni otkloneniya parametrov metabolizma zheleza i e´ritropoe´tina u anemichnikh bol´nykh s khronicheskoj serdechnoj nedostatochnost´yu: fokus na diabeticheskuyu nefropatiyu [Complex assessment of deviations of the parameters of iron metabolism and erythropoietin in anemic patients with chronic heart failure: focus on diabetic nephropathy]. Problemy endokrinnoi patolohii, 3, 41–47. [in Russian].
Ryndina, N. G. (2013) Osoblyvosti struktury anemichnoho syndromu u khvorykh na khronichnu sertsevu nedostatnist riznoho funktsionalnoho klasu [Structure of anemic syndrome in patients with chronic heart failure of different functional class]. Odeskyi medychnyi zhurnal, 3(137), 49–52. [in Ukrainian].
Parhomenko, A. N., & Kozhukhov, S. N. (2014). Rezul´taty otkrytogo randomozirovannogo issledovaniya po izucheniyu perenosimosti i e´fektivnosti preparata Korvitin® u pacientov s zastojnoi serdechnoj nedostatochnostiyu i sistolicheskoj disfunkciei levogo zheludochka [Results of an open, randomized study of the tolerability and efficacy of Corvitin in patients with congestive heart failure and left ventricular systolic dysfunction]. Ukrainskyi medychnyi chasopys, 4(102), 71–76. [in Russian].
Kravchun, P.G., Lapshina, L. A., & Zolotaikina, V. I. (2012) Dinamika urovnej lejkotriena С4, faktorov nespecificheskogo vospaleniya, markerov oksidativnogo stressа, kardiogemodinamiki pri vkluchenii vodorastvorimoj formy kvercitina v terapiyu ostroj serdechnoj nedostatochnosti [Dynamic of levels of factors of non-specific inflammation (TNF-α, IL-6, CRP), markers of oxidative stress, cardiohemodynamics in adding of inhibitors of 5-lypoxigenase quercetin in therapy of acute heart failure]. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya «Medicina. Farmaciya», 4(123), 17, 100–109. [in Russian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
